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LIST OF ABBREVIATIONS: 
BHQ:  Bronchiectasis Health Questionnaire 
BSI:  Bronchiectasis Severity Index 
CAT:   chronic obstructive disease (COPD) assessment tool 
COPD:  chronic obstructive pulmonary disease 
CI:  confidence interval 
CT:  computed tomography 
DIF:  differential item functioning 
FEV1:   forced expiratory volume in 1 second 
FVC:   forced vital capacity 
ICC:  intraclass correlation coefficient 
K-BILD:  King’s Brief Interstitial Lung Disease  
LCQ:   Leicester Cough Questionnaire 
MCID:  minimal clinically important difference 
MRC:  Medical Research Council 
PSI:   Person Separation Index 
QOL-B: Quality of Life-Bronchiectasis 
SD:   standard deviation 
SGRQ: St George’s Respiratory Questionnaire 
VAS:   visual analogue scale 
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ABSTRACT 
Background: Health-related quality of life or health status is significantly impaired in 
bronchiectasis. There is a paucity of brief, simple to use, disease-specific health status 
measures. The aim of this study was to develop and validate the Bronchiectasis Health 
Questionnaire (BHQ), a new health status measure that is brief and generates a single overall 
score. 
Methods: Patients with bronchiectasis were recruited from two outpatient clinics, during a 
clinically stable stage. The development of the questionnaire followed three stages: item 
generation and item reduction using Rasch analysis; validation; and repeatability testing. The 
BHQ was translated into eleven languages using standardised methodology. 
Results: 206 patients with bronchiectasis completed a preliminary 65-item questionnaire. 
Fifty-five items were removed due to redundancy or poor fit to the Rasch model. The final 
version of the BHQ consisted of 10 items. Internal consistency was good, Cronbach’s α 
coefficient 0.85. Convergent validity of the BHQ with St George’s Respiratory Questionnaire 
was high (r=-0.82, p<0.001) and moderate with lung function (FEV1 % predicted r=-0.27, 
p=0.001). There was a significant association between BHQ scores and number of 
exacerbations of bronchiectasis in the last 12 months (p<0.001), hospital admissions 
(p=0.001) and CT scan bronchiectasis pulmonary lobe counts (p<0.001). BHQ scores were 
significantly worse in patients with sputum bacterial colonisation vs. no colonisation 
(p=0.048).  The BHQ was highly repeatable after 2 weeks, intraclass correlation coefficient 
0.89.  
Conclusions: The BHQ is a brief, valid and repeatable, self-completed health status 
questionnaire for bronchiectasis that generates a single total score. It can be used in the clinic 
to assess bronchiectasis from the patient’s perspective.  
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INTRODUCTION 
Bronchiectasis is a persistent or progressive condition that is characterised by dilated, and 
often thick-walled bronchi [1]. Symptoms of bronchiectasis include breathlessness, cough, 
sputum production and haemoptysis. The severity of bronchiectasis can be assessed with 
physiological, radiological and composite measures such as the Bronchiectasis Severity Index 
(BSI) and the FACED score [2, 3]. The patient’s perception of the condition is also important 
[4, 5]. Health status or health-related quality of life is defined as “the perception of the impact 
of health on an individual’s contentment or satisfaction with life in areas they consider 
important” [6]. Health status is significantly impaired in bronchiectasis [7, 8]. It can be assessed 
and quantified with validated questionnaires [9, 10]. They can be used to improve 
communication between a patient and their clinician, target therapy to specific areas of health 
and evaluate the effectiveness of treatment [11].  
 
A recent systematic review has identified several validated health status questionnaires that 
can be used in bronchiectasis, such as the disease-specific Quality of Life-Bronchiectasis 
(QOL-B), and non-disease specific St George’s Respiratory Questionnaire (SGRQ) and 
Leicester Cough Questionnaire (LCQ) [8, 10, 12-14]. These questionnaires have limitations of 
being relatively long, don’t generate a total score (QOL-B) and are not disease-specific 
(SGRQ, LCQ) [8]. There has been a trend recently to develop brief health status tools with 
simple overall scores, so that they are practical for clinical use [15]. The increasing use of 
item-response theory methodology to develop health status questionnaires has facilitated 
briefer tools. One such method uses Rasch analysis, facilitating the creation of 
unidimensional scales with interval scaling properties [16]. Examples include the chronic 
obstructive disease (COPD) assessment tool (CAT) and King’s Brief Interstitial Lung 
Disease questionnaire (K-BILD) [15, 17]. We set out to develop and validate a bronchiectasis-
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specific health status questionnaire. Our aim was to develop a well validated tool that was 
brief and easy to administer and interpret, with a single overall score. 
 
METHODS 
Phase 1: item generation 
A preliminary Bronchiectasis Health Questionnaire (BHQ) was developed following: 1. a 
systematic literature review of health status questionnaires in bronchiectasis and review of 
other health status measures [8]; 2. face-to-face semi-structured interviews with 12 
consecutive patients with bronchiectasis; 3. feedback from a multidisciplinary team 
consisting of respiratory physicians, respiratory physiotherapists, a nurse, a pharmacist and a 
sociologist. The aim of the interviews was to identify relevant issues and topics to inform the 
item generation. The interviews began with open-ended questions and continued with more 
specific topics. Examples of open-ended questions were: Can you describe what it is like to 
have bronchiectasis? How does it affect your everyday life? The interviews were conducted 
until saturation (no new items were emerging) [10]. Patients were asked to complete and 
comment on a preliminary version of the questionnaire. The items of the questionnaire 
referred to the last 14 days and responses were selected from a 7-point Likert scale. The 
response scales for items whose high scores represented poor health status were reversed to 
ensure high scores represented good health status for consistency of analysis. 
Participants 
The preliminary BHQ was evaluated in patients with bronchiectasis attributed to various 
aetiologies, excluding cystic fibrosis. Consecutive patients were recruited prospectively from 
secondary care (King’s College Hospital) and tertiary care (Royal Brompton Hospital) 
7 
  
specialist clinics from November 2012 to August 2014. Patients reporting an exacerbation of 
their bronchiectasis in the previous 2 weeks were excluded. A sub-study was conducted in an 
independent group of consecutive patients in a specialist bronchiectasis clinic in China 
(Guangzhou) to assess the clinical properties of a translated BHQ (patient interviews, internal 
reliability and construct validity) by assessing the relationship with computed tomography 
(CT) scan affected pulmonary lobe count. Demographics and clinical characteristics were 
recorded. Patients completed the preliminary BHQ, SGRQ and visual analogue scales (VAS, 
0-100 mm) for severity of breathlessness, cough and sputum, independently when attending 
their routine clinical appointment. A researcher who was not involved in the clinical care of 
the patient administered the questionnaires. Patients were excluded from the study if they 
could not read the questionnaire or completed less than 85% of the items. The diagnosis of 
bronchiectasis was the first and main aetiology and was based on clinical characteristics and 
CT scan, consistent with the British Thoracic Society guidelines [1]. Sputum colonisation 
status was recorded using the clinical records of the most recent sputum analyses. Sputum 
bacteria colonisation was assessed and defined as at least 2 positive cultures, minimum 3 
months apart and within one year [2]. All patients provided written informed consent and the 
study was approved by the Research Ethics Committee London - Queen Square (Research 
Ethics Committee Reference Number 12/LO/1437).  
Phase 2: item reduction, Rasch analysis and validation 
Items were removed if there was a significant floor effect or ceiling effect response ≥50% [18]. 
Items with missing values ≥5% were eliminated. The weaker items of highly inter-correlated 
item pairs (r>0.8) were removed by face validity [17].    
Rasch analysis 
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Rasch analysis assesses the fit of a questionnaire to a unidimensional model [19]. A 
questionnaire that fits the Rasch model has interval scaling properties. Rasch analysis is 
based on the theory that the response to an item is governed by two factors: the level of 
ability of the person and the level of difficulty represented by the item. Patients are more 
likely to respond to items of lower difficulty (less severe health status) and less likely to more 
difficult items (more severe health status). Rasch analysis was performed for the development 
of BHQ and items that did not meet the model were removed. This involved an iterative 
statistical process where the item with the poorest fit to the model was removed and the 
remaining items retested until a reliable and unidimensional scale was identified. The item-
trait interaction was used to assess the questionnaire fit to a unidimensional model. Items 
were removed if they did not fit to the model, indicated by a significant χ2 test for the overall 
item-trait interaction or individual items. The summation of the difference between the 
observed and expected scores for all persons, called item fit residuals ≤-2.5 or ≥2.5 indicated 
items that did not measure the same attribute as the domain being tested and were also 
removed. Summary item fit residuals and person fit residuals were item-person interaction 
statistics transformed to approximate a z score; mean (SD) residual of approximately 0 (1) 
indicated good fit to the model. The Person Separation Index (PSI) aimed to assess the ability 
of BHQ to discriminate patients with different levels of health status impairment and test the 
reliability of the fit statistics. Internal consistency was assessed using Cronbach’s α 
coefficient. Likert response scale weightings for individual items were combined if necessary 
to ensure they detected progressive changes in health status. The BHQ total score was 
obtained following logit transformation of raw responses and it was then transformed to a 
range of 0-100; 100=best health status. Differential item functioning (DIF) was evaluated to 
assess the influence of age, gender, aetiology of bronchiectasis and forced expiratory volume 
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in 1 second (FEV1) % predicted. The final version for the BHQ was retested with Rasch 
analysis. 
Construct validity 
Construct (convergent/divergent) validity, an assessment of an instrument against other 
standards that provide an indication of the true value of measurements, was assessed by 
investigating the relationship between the final BHQ and lung function, CT scan 
bronchiectasis pulmonary lobe count, exacerbations, hospitalisations, sputum bacterial 
colonisation, symptom scales and other health status questionnaires. Spirometry was assessed 
within 6 months of completion of the BHQ. Patients completed the SGRQ, which is a 
respiratory-specific health status questionnaire originally developed for patients with COPD. 
The SGRQ has been validated in bronchiectasis and has been the most widely used 
questionnaire in this condition [8, 9]. Patients also completed 3 symptom severity visual 
analogue scales (VAS, 0-100 mm) for breathlessness, sputum and cough (time frame last 2 
weeks) [11]. The BHQ was administered first, and the SGRQ and VAS were completed in a 
random order. All measurements were performed prior to patients seeing the doctor. CT scan 
bronchiectasis pulmonary lobe counts were assessed by an experienced pulmonary radiologist 
blinded to clinical details in an independent group of patients, in a centre in China 
(Guangzhou), in whom CT scan was available within the past 12 months. 
 
Repeatability 
To investigate the repeatability of the BHQ, a subgroup of unselected, consecutive patients 
completed the BHQ on two occasions, 2 weeks apart. Only patients whose condition was 
considered clinically stable by both clinician and patient were recruited (patients reporting 
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their condition was unchanged on a global rating of change scale). Patients were excluded if 
they had an upper or lower tract respiratory infection or change of medication within the 
previous 2 weeks.  
 
BHQ translations 
The BHQ was translated into 11 languages by MAPI Language Services (Lyon, France), 
specialists in health status questionnaire translation; nine Indo-European (Dutch for Belgium 
and The Netherlands, English for the USA, French for Belgium and France, German, Italian, 
and Spanish for Spain and the USA), one Japonic (Japanese), and one Sino-Tibetan 
(Mandarin). In each country, the following translation method (i.e., linguistic validation) was 
used: 1. in-depth analysis of the original (i.e., concept definition) and suggestion of suitable 
translation alternatives; 2. forward/backward translation step (or adaptation for English and 
Spanish versions), 3. review of back translation by the developer and 4. review of translated 
questionnaire by a respiratory clinician fluent in the language. The clinical properties of a 
translated BHQ were assessed further in a single centre in China (Mandarin): patient 
interviews, internal reliability and construct validity (association with CT scan pulmonary 
lobe scores).  
Analysis 
SPSS Version 22.0 (Chicago, US), GraphPad Prism 5 (California, US), and RUMM2030 
(RUMM Laboratory Pty Ltd) were used for statistical analyses. Mean (standard deviation, 
SD) was used as descriptive statistics for parametric distributions and median (interquartile 
range, IQR) for non-parametric distributions. Significance was set as p<0.05. Correlations 
between parameters were assessed with Pearson’s coefficient (r) and Spearman rho (ρ). 
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Univariate analysis was performed to identify associations between health status and age, 
gender, bronchiectasis aetiology and colonisation status. Repeatability of the BHQ was 
assessed with intraclass correlation coefficients (ICC) and a Bland Altman plot. The 95% 
limits of agreement were calculated as 1.96×SD of within-subject differences. D’Agostino 
and Pearson omnibus normality test was used to assess distribution of data. A minimum 
completion of 8 out of 10 items was necessary to generate a BHQ score. The average item 
score (rounded) of the remaining items was used for missing items. 
 
RESULTS 
Phase 1: Item generation and subject characteristics 
Twelve patients with bronchiectasis (online supplement appendix 1, Table e1) were 
interviewed to identify common themes and items; and interviews were discontinued when 
they did not yield new items (online supplement appendix 1, Table e2). A preliminary version 
of the BHQ consisting of 65-items was developed following the item generation process 
(online supplement appendix 1, Table e3). The preliminary items covered topics that included 
respiratory symptoms, functional capacity, psychological health, medications and treatments, 
relationships and social function. The response scale timeframes were developed from 
multidisciplinary team discussion. The preliminary questionnaire was evaluated in four 
patients with bronchiectasis to assess item wording and no further changes were made. 
The BHQ was administered to 221 patients with bronchiectasis to investigate validity. Fifteen 
patients (7.3%) completed less than 85% of the questionnaire and were excluded (visually 
impaired, language difficulty, reasons not recorded). The remaining patients did not report 
any difficulty in completing the BHQ. Demographic and clinical characteristics of the 
participants are presented in table 1.  
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Phase 2: Item reduction and Rasch analysis  
The item reduction process is summarised in figure 1. Two items were removed due to 
missing responses >5%, 19 items due to significant floor effect and 3 items due to ceiling 
effect. Three items were removed because of high item-item correlation. Rasch analysis 
removed 26 poor fitting items. There was no individual item misfit in the remaining items 
and the item-trait interaction was non-significant, indicating good fit to the Rasch model. The 
summary statistics for the final 10-item version of the BHQ indicated a good fit to the model 
(table 2 and figure 2). The Person Separation Index (PSI) for BHQ total score was 0.85, 
suggesting it had good discriminant power to detect differing levels of health impairment. A 
person-item map indicated that BHQ items detected health status across a wide spectrum of 
health status severity (online supplement appendix 1, figure e1). There was no influence of 
age, gender, bronchiectasis aetiology and FEV1 % predicted on the response to items (DIF). 
The response scales for 8 items were disordered and corrected to a progressive scale. The 
mean (SD) BHQ score was not significantly different in patients with bronchiectasis with co-
existing respiratory comorbidities (asthma, COPD, sarcoidosis, pulmonary fibrosis and lung 
surgery) 58.3 (11.8) vs. those with no respiratory comorbidities 60.1 (11.8), mean difference 
1.9, 95% confidence interval (CI) of difference -1.9 to 5.6, p=0.323.  
Validation 
The mean (SD) BHQ total score (10 item) was 60.0 (11.9). The BHQ correlated strongly with 
SGRQ (all domains and total score) and VAS-dyspnoea, moderately with VAS-cough and 
VAS-sputum and weak-moderately with lung function (table 3). The association between 
BHQ and SGRQ total score remained unchanged when patients with COPD were excluded; 
r=-0.826, p<0.001. There were significant differences in BHQ scores between categories of 
FEV1 % predicted, ANOVA p=0.007 [mean (SD) BHQ score for group FEV1<50% 55.6 (9.5) 
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vs. FEV1>80% 64.1 (11.1); mean difference 8.5, 95% CI of difference 1.7 to 15.1, p=0.008, 
figure 3]. There were no significant differences in BHQ scores between FEV <50 vs. 50-80 
and >80 vs. 50-80% (p>0.05). There were no significant differences in BHQ scores between 
gender (p=0.48) or bronchiectasis aetiology (p=0.23). BHQ score did not correlate with age 
(r=-0.04, p=0.57). The mean (SD) BHQ score was worse in patients with sputum colonisation 
(any micro-organism) 57.5 (10.2) vs. no colonisation 61.1 (12.7); mean difference 3.6, 95% 
CI 0.04 to 7.20, p=0.048. The mean (SD) BHQ score in patients with sputum Pseudomonas 
aeruginosa colonisation was 57.4 (9.9) vs. no colonisation 61.1 (12.7); mean difference 3.7, 
95% CI -0.04 to 7.4, p=0.053. BHQ scores were significantly associated with exacerbations 
and hospitalisation in the last 12 months related to bronchiectasis, see Table 3, figure 4 and 
figure e2 in online supplement appendix 1. The mean (SD) BHQ was lower (worse) in 
patients reporting exacerbations within the last 12 months 58.8 (11.4) vs. no exacerbations 
68.4 (11.6); mean difference 9.6, 95% CI of difference 4.9 to 14.3, p<0.001 (figure 4). The 
mean (SD) BHQ was lower in patients reporting hospital admissions for bronchiectasis 
within the last 12 months 54.0 (10.9) vs. no hospital admission 61.8 (11.7); mean difference 
7.8, 95% CI of difference 3.8 to 11.8, p<0.001 (online supplement appendix 1, figure e2). 
There was a significant association between BHQ scores and CT scan bronchiectasis 
pulmonary lobe count in the sub-study group of patients (n=56, online supplement appendix 
1, Table e4); ρ= -0.478, p<0.001.  
 
Repeatability 
Repeatability was investigated in 32 patients. Intraclass correlation coefficients (ICC) were 
consistent with good repeatability; ICC (95% CI) 0.89 (0.77, 0.94), p<0.01). A Bland-Altman 
plot of BHQ score repeatability is shown in figure5.  
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Translation 
The translation process did not reveal any cultural issues since most of the concepts assessed 
were cross-culturally relevant. The main difficulties consisted in finding conceptual 
equivalents to the response choices designed as Likert-type scales in 7 points (e.g., “All of the 
time” to “None of the time”). In all countries, translators ensured that the continuity of time 
was kept between all versions using either adverbs or synonyms (e.g., “Always” for “All of 
the time”). Items 2, 4 and 10 were the items that raised most discussion across languages for 
idiomatic or syntactic reasons. Solutions were found in order to respect the structure and 
common use of each target language. The clinicians’ review proved useful to clarify the 
concept of “clear chest” in item 4, i.e., meaning “chest clear of sputum or congestion,” and 
led to changes in wording. There were only minor changes to the wording of Chinese BHQ 
following patient interviews. The alpha Cronbach coefficient for Chinese BHQ (internal 
reliability) was 0.78, comparable to the original BHQ. See online supplement appendix 2 for 
copies of all translated BHQs.  
 
DISCUSSION 
The BHQ is a health status questionnaire developed and validated specifically for patients 
with bronchiectasis. The questionnaire items were selected using item-response theory to 
create a unidimensional scale with interval scaling properties. The BHQ is brief, containing 
just 10 items, and generates a single overall health status score. It is simple to administer and 
most patients found it easy to complete.   
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The BHQ items were generated following detailed patient interviews exploring the impact of 
their lung condition on their health. The preliminary BHQ was assessed using a systematic 
statistical approach with Rasch analysis, commonly used in the development of health status 
tools. Items that did not conform to a unidimensional scale were eliminated. Redundant items 
were also removed, if possible, whilst retaining essential questionnaire measurement 
characteristics. Rasch analysis confirmed that the BHQ had good internal scaling of items and 
was unidimensional. Unidimensional scales are an important attribute of health status 
questionnaires because they confirm that the instrument measures the intended construct, and 
allows health status to be quantified as a single number to facilitate clinical utility and 
interpretation. The convergent validity of the BHQ (association with the SGRQ) was good, 
suggesting that the removal of redundant items did not compromise the BHQ’s ability to 
measure health status. The BHQ also correlated well with VAS scales for breathlessness and 
moderately for cough and sputum scales. The internal consistency of the BHQ was good, and 
above the recommended threshold for health status questionnaires [20]. The BHQ scores were 
worse in patients with frequent exacerbations and hospital admissions in the last 12 months 
due to their bronchiectasis and also in those with more extensive disease on CT scan and 
sputum colonisation with micro-organisms. The BHQ was highly repeatable over 2 weeks, 
but further studies are needed to determine this over a longer duration.   
 
The association between health status and lung function (FEV1), although statistically 
significant, was weak. This is not surprising because health status and measures of lung 
physiology are very different domains of health. This weak relationship is similar to that 
reported in other chronic respiratory disorders, such as COPD [21]. A weak association with 
FEV1 has also been reported for the QOL-B questionnaire 
[7, 10]. Our findings suggest that 
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health status questionnaires assess a unique aspect of disease severity not captured by 
objective measures. 
 
The QOL-B is the only other bronchiectasis-specific health status questionnaire that has 
recently been published and validated [7, 10]. The QOL-B comprises 37 items and the scores 
are presented as 8 distinct domains. There are several differences between the QOL-B and the 
BHQ. The QOL-B is a considerably longer questionnaire, and does not provide an overall 
health status score. The BHQ may therefore be more suitable for clinical and research 
settings where a brief questionnaire is an important practical consideration, and when a single 
score is desirable for ease of clinical interpretation, such as evaluating the response to 
therapeutic interventions. In contrast, the QOL-B may be more advantageous when in-depth 
analysis of health status is required, and when there is a need to identify impairment in 
specific health domains. The questionnaires differ in the methodology used to eliminate items 
from the preliminary questionnaire to generate the final version. For the QOL-B, item 
reduction was based on subjective methodology. This may have retained items clinicians and 
patients consider important, but it is a method that doesn’t select items on their scaling 
properties. In contrast, the BHQ used Rasch analysis to eliminate items systematically. The 
validity reported for both questionnaires, such as convergent validity (correlation coefficient 
with SGRQ, QOL-B -0.38 to -0.85 vs. BHQ -0.82), internal consistency (Cronbach’s α, 
QOL-B 0.66 to 0.94 vs. BHQ 0.85) and repeatability (ICC, QOL-B 0.67 to 0.88 vs. BHQ 
0.89) is generally comparable [7, 8, 10, 22, 23]. This suggests that the removal of redundant items 
to create a very brief tool has not compromised the measurement characteristics of the BHQ. 
There were some differences in the patient populations in which both questionnaires were 
validated. The BHQ was validated in an unselected population with bronchiectasis. The 
QOL-B was validated in clinical trials that selected participants who had cultured gram-
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negative sputum organisms [7, 10, 22]. We were unable to compare the performance of the BHQ 
against the QOL-B since it was not available at the time of this study. Future studies 
comparing the performance of BHQ, SGRQ and QOL-B questionnaires are needed to address 
this limitation, particularly longitudinal assessment, treatment responsiveness and association 
with disease severity tools such as the BSI. 
 
The SGRQ and LCQ are two other health status questionnaires widely used in the assessment 
of bronchiectasis [8, 9, 24]. Although they were developed for use in other chronic respiratory 
conditions, they have been well validated in patients with bronchiectasis. The internal 
reliability, construct validity and repeatability of the BHQ is comparable to that of the SGRQ 
and the LCQ [8, 9, 25]. The SGRQ is a considerably longer comprising of 50 items, and has a 
greater focus on breathlessness [14]. The LCQ also has a greater number of items (19) and its 
main focus is on health status related to cough [13]. There is overlap in the content of 5 items 
between the LCQ and BHQ. The BHQ however focuses specifically on symptoms of 
bronchiectasis, and both breathlessness and cough are represented. A comparative study of 
the BHQ and LCQ is needed to determine if assessment of health status with the BHQ covers 
the domains of the LCQ.   
 
We have translated the BHQ into 11 other languages using standardised methodology. The 
translations were conducted by experts (MAPI, France) who are experienced in adapting 
health status questionnaires for use in a wide range of countries. We also sought the input of 
pulmonary clinicians familiar with bronchiectasis who were literate in these languages. Our 
translation methodology should be considered the first step in the cultural adaptation of the 
BHQ. Further independent evaluation of the translated BHQ is necessary to obtain the 
feedback of patients and also determine its validity, such as the internal consistency. We did 
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assess the validity of the Chinese language BHQ with patient interviews and assessment of 
construct validity and internal reliability; this was consistent with the original English 
language BHQ. The publication of a health status questionnaire from the outset in multiple 
languages may be advantageous in ensuring the standardisation and the quality of the 
translation [see online supplementary appendix 2 for copies of the translated BHQ in French, 
Dutch, German, Italian, Spanish, Japanese, Chinese (simplified Mandarin), Belgian (French, 
Dutch), US-Spanish and US-English].  
 
There are some limitations with health status questionnaire development methodology. We 
used Rasch analysis to eliminate items that did not fit a unidimensional model. We eliminated 
items that were infrequent, redundant or contributed weakly to health status assessment, or 
did not conform to optimal scaling properties. We may have eliminated items important to 
patients that may have been retained using methodology based on clinical importance [26]. 
Our aim was to develop a brief questionnaire that could quantify health status with the least 
number of items, while retaining validity, so that it was practical for clinical use. Health 
status questionnaires are not a substitute for identifying health-related issues obtained from a 
detailed history. The prevalence of idiopathic bronchiectasis in our study was high, 41%. 
Whilst this may reflect difficultly in identifying causes, the prevalence was similar to 44% 
reported in a recent systematic review of 8,608 patients [27]. There are a number of well 
validated tools now available to assess the severity of bronchiectasis, such as the 
Bronchiectasis Severity Index (BSI) and FACED tools [2, 3]. We were unable to 
retrospectively assess these scores because some of the clinical components of these scores 
were not available or were significantly out of date. We did not assess the extent of 
bronchiectasis since the duration between CT scan and study assessments was considerable 
for many patients. The BSI and FACED tools assess disease severity, which is distinct from 
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health status measures. We did however find a significant association between the BHQ and 
FEV1 and breathlessness, components of both severity tools. To our knowledge, the 
association between QOL-B and BSI or FACED scores has also not been reported. Further 
studies should investigate the relationship between the BSI and FACED and health status 
assessed with the BHQ.  
 
The responsiveness and the minimal clinically important difference (MCID) of the BHQ have 
not been studied and this needs investigation [28]. The MCID is essential for clinical 
interpretation of BHQ scores and therefore the BHQ is likely to be limited to a research tool 
until this is defined. The high Person Separation Index (PSI) for the BHQ was however 
consistent with ability to discriminate differing levels of health status. The sample size of 
patients (12) interviewed was small and it is possible some themes relevant to patients were 
missed. The sample was small since the interviews were in depth and but it was similar to the 
development of other health status tools such as the LCQ. We were able to generate a large 
preliminary BHQ questionnaire comprising 65 items that covered a broad range of health 
domains. It is possible that the presence of co-morbidities, such as asthma, COPD, aspergillus 
colonisation and immunoglobulin deficiency may have impacted the assessment of health 
status. The BHQ items however were worded specifically to relate to the patient’s 
bronchiectasis. The patients were recruited from bronchiectasis clinics and bronchiectasis 
was the primary diagnosis. Our patients had mild physiological impairment and it is possible 
this may have had an impact on the development of the BHQ. The recruitment of a large 
sample size (n=206), patients with a wide range of physiological impairment (lowest FEV1 
18% predicted) and the lack of differential item functioning (DIF) with FEV1 suggests this is 
unlikely. We did not assess the relationship between BHQ scores and the presence of 
clinically significant non-tuberculous mycobacterium; this should be assessed in future. A 
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potential disadvantage of the BHQ is that it does not quantify health status in specific health 
domains, such as psychological, activity and social. We did, however, set out to develop a 
very brief and practical health status questionnaire with a single overall score. A detailed 
assessment of health domains can be achieved with other questionnaires. The purpose of 
question 10 (number of antibiotics taken for chest or respiratory infections in 12 months) was 
to capture the impact of frequent respiratory infections on health status. Question 10 may be 
less responsive when repeated over a shorter time interval. The BHQ does have 9 other items 
that assess over a short interval; hence the impact of one item is likely to be limited. Patients 
taking long term antibiotics may have difficulty in answering question 10. We did not 
encounter any issues during patient interviews or administration of the questionnaire in a 
large number of patients; they were able to relate this item to acute infections. The BHQ has 
been evaluated in only 3 centres and therefore an external validation, including more overseas 
centres is essential in future studies, given the heterogeneous nature of bronchiectasis.     
 
The BHQ has a number of potential applications. It is a quick and valid tool to identify health 
status issues important to patients in the clinic. It can be used to help formulate shared care 
plans between the patient and the physician. In summary, the BHQ is brief, easy to administer 
and well-validated.  
 
 
 
Reprints of BHQ: Bronchiectasis Health Questionnaire 2014 is protected by copyright; 
King’s College Hospital NHS Foundation Trust. Reprints of the BHQ and scoring program 
are available from the corresponding author. 
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Table 1. Patient demographics and clinical characteristics (n=206). 
 All patients 
Age, years  59  ±15 
Female % 65 
BMI kg/m2  25 ± 5 
Smoking status %  
   Current 1 
   Ex 23 
   Never 76 
Bronchiectasis aetiology %              
   Idiopathic  41 
   Post-infective 27 
   Immunodeficiency 11 
   ABPA 8 
   Other# 13 
Spirometry  
   FEV1 % pred.              75 ± 28 
   FVC % pred.  91 ± 25 
   FEV1/FVC 66 ± 14 
Sputum colonisation with micro-organisms $ %  
   Pseudomonas aeruginosa 26 
   Other  24 
   None 61 
Exacerbations/12 months (%)  
   0 13 
   1 12 
   2 15 
   3 17 
   4 11 
   5 10 
   >5 22 
Hospitalisations/12 months (%)  
   0 79 
   1 11 
   2 4 
   3 1 
   4 2 
   5 1 
   >5 2 
Comorbidities %  
   Asthma 25 
   Rhinosinusitis 23 
   Cardiovascular  14 
   COPD 9 
26 
  
   Lung Surgery 6 
   Diabetes mellitus  4 
   Lung fibrosis/sarcoidosis 3 
   Malignancy 1 
Respiratory Symptoms  
   VAS Dyspnoea* 27 (10, 53) 
   VAS Cough* 28 (12, 53) 
   VAS Sputum* 30 (11, 56) 
SGRQ  
   SGRQ Total    43 ± 20 
   SGRQ Activities 50 ±27 
   SGRQ Symptoms 63 ±21 
   SGRQ Impact 33 ±20 
 
Data presented as mean ±SD unless otherwise stated.  
*: data presented as median (IQR).  
#: Other aetiologies (total n=27) consist of primary ciliary dyskinesia (n=10), Kartagener’s 
syndrome (n=2), inflammatory bowel disease (n=5), rheumatoid arthritis (n=6), Young’s 
syndrome (n=3) and yellow nails syndrome (n=1).  
$: Sputum colonisation status does not add up to 100% as participants could be chronically 
infected with Pseudomonas aeruginosa and other micro-organisms. Sputum bacteria 
colonisation was assessed and defined as at least 2 positive cultures, minimum 3 months apart 
and within one year. 
Comorbidities do not add up to 100% as participants could have no comorbidities or more 
than one comorbidities. 
ABPA: allergic bronchopulmonary aspergillosis, BMI: body mass index, COPD: chronic 
obstructive pulmonary disease, FEV1: forced expiratory volume in 1 second (range 18.1 to 
150.7%), FVC: forced vital capacity, IQR: interquartile range, VAS: visual analogue scale, 
SGRQ: St George’s Respiratory Questionnaire.   
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Table 2. Summary of Rasch analysis. 
Rasch statistics BHQ total score 
Number of items 10 
χ2 fit statistic  28.16 
Degrees of freedom  20 
P value  0.11 
Mean item fit residual (SD)  0.01 (1.11) 
Mean person fit residual (SD) -0.25 (1.11) 
PSI   0.85 
Cronbach’s α coefficient  0.85 
 
χ2 statistic assesses item-trait interaction; non-significance indicates a good fit to the Rasch 
model (p>0.05). The mean person and item fit residuals are item-person interaction statistics 
that are z transformed; a good fit to the Rasch model is when they approximate to a mean 
(SD) of 0 (1). The Person Separation Index (PSI) assesses how well BHQ discriminates 
subjects with differing levels of health status. Cronbach’s α coefficient is a measure of 
internal reliability. A PSI and Cronbach’s α coefficient ≥0.7 is considered acceptable. 
BHQ: Bronchiectasis Health Questionnaire, PSI: Person Separation Index, SD: standard 
deviation. 
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Table 3. The relationship between Bronchiectasis Health Questionnaire (BHQ) and clinical 
measures. 
 BHQ 
(correlation 
coefficient) 
P value 
 
FEV1 % predicted 
 
0.266 
 
0.001 
FVC % predicted 0.252 0.003 
Exacerbations/12 months -0.486 <0.001 
Hospitalisations/12 months -0.328 0.001 
SGRQ Total -0.819 <0.001 
SGRQ Activities -0.704 <0.001 
SGRQ Symptoms  -0.710 <0.001 
SGRQ Impact -0.779 <0.001 
VAS Dyspnoea* -0.703 <0.001 
VAS Cough* -0.613 <0.001 
VAS Sputum* -0.481 <0.001 
 
N=206. Data shown are Pearson’s correlation coefficients (r) unless otherwise stated; all 
p<0.01. 
*: Spearman’s rho (ρ). 
FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, SGRQ: St George’s 
Respiratory Questionnaire, VAS: visual analogue scale.  
Exacerbations and hospitalisations related to bronchiectasis. 
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FIGURES LEGENDS 
 
Figure 1. Summary of the development of the Bronchiectasis Health Questionnaire (BHQ). 
Figure 2. The Bronchiectasis Health Questionnaire (BHQ). 
Figure 3. Bronchiectasis Health Questionnaire (BHQ) scores for forced expiratory volume in 
1 second (FEV1) categories.  
Figure 4. The association between exacerbations of bronchiectasis and Bronchiectasis Health 
Questionnaire (BHQ) scores. 
Figure 5. Bland Altman plot of repeatability of the Bronchiectasis Health Questionnaire 
(BHQ). 
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Figure 1. Summary of the development of the Bronchiectasis Health Questionnaire (BHQ). 
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Figure 2. The Bronchiectasis Health Questionnaire (BHQ). 
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Figure 3. Bronchiectasis Health Questionnaire (BHQ) scores for forced expiratory volume in 
1 second (FEV1) categories.  
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Data presented as mean (standard deviation).  
BHQ: Bronchiectasis Health Questionnaire, FEV1: forced expiratory volume in 1 second. 
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Figure 4. The association between exacerbations of bronchiectasis and Bronchiectasis Health 
Questionnaire (BHQ) scores. 
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N=206. Data presented as mean (standard deviation).   
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Figure 5. Bland Altman plot of repeatability of the Bronchiectasis Health Questionnaire (BHQ).   
 
N=32. Solid line represents mean BHQ difference and dotted lines represent 95% limits of agreement.  
The 95% limits of agreement were calculated as mean ± (1.96×SD) of within-subject differences.  
